Alefacept

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Immunosuppressively active fusion protein (dimer) consisting of an extracellular CD2 binding site of leukocyte functional antigen 3 (LFA-3) and portions of IgG1

Pharmacodynamics (Effect)This section has been translated automatically.

Inhibition of lymphocyte activation by specific binding to CD2 and inhibition of LFA-3/CD2 interaction. Reduction of CD2+ T lymphocytes, especially CD45 RO+ cells, probably by binding of CD2 to target cells and the Fc fragments on cytotoxic cells, especially NK cells.

IndicationThis section has been translated automatically.

For moderately severe and severe forms of psoriasis vulgaris that require systemic treatment ( off-label use, not permitted in Europe!).

Pregnancy/nursing periodThis section has been translated automatically.

Insufficient data on use in pregnancy and lactation are available. Should not be prescribed during pregnancy and lactation.

Complication(s)This section has been translated automatically.

Lymphocytopenia (dose-dependent, especially with CD4 and CD8 cells)!

Cave! Weekly control of lymphocyte subpopulations, especially CD4 lymphocytes in the differential blood count!

Dosage and method of useThis section has been translated automatically.

Once/week 7.5 mg Alefacept i.v. or once/week 15 mg i.m. for 12 weeks.If necessary, repeat the therapy cycle after a 12-week therapy break.

ContraindicationThis section has been translated automatically.

Lymphocytopenia with planned therapy start.

PreparationsThis section has been translated automatically.

Amevive

LiteratureThis section has been translated automatically.

  1. Cather JC et al (2003) Investigational therapies for psoriasis. J Am Acad Dermatol 49: S133-138
  2. Craze M et al (2003) Integrating biologic therapies into a dermatology practice: practical and economic considerations. J Am Acad Dermatol 49: S139-142
  3. Frampton J, Wagstaff A (2003) Alefacept Am J Clin Dermatol 4: 277-286
  4. Gottlieb AB (2003) CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 49: 816-825
  5. Gottlieb AB, Bos JD (2002) Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 105: 105-116
  6. Krueger GG, Ellis CN (2003) Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 148: 784-788
  7. Krueger GG, Callis KP (2003) Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 49: S87-97
  8. Vaishnaw AK et al (2002) Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 29: 415-426
  9. Weinberg JM, Tutrone WD (2003) Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept. Cutis 71: 41-45

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer